Recent advances in bioinformatics promote drug-design methods that aim to reduce side-effects. Efficient computational methods are required to identify the optimal enzyme-combination (i.e., drug targets) whose inhibition, will achieve the required effect of eliminating a given target set of compounds, while incurring minimal side-effects. We formulate the optimal enzymecombination identification problem as an optimization problem on metabolic networks. We define a graph based computational damage model that encapsulates the impact of enzymes onto compounds in metabolic networks. We develop a branch-and-bound algorithm, named OPMET, to explore the search space dynamically. We also develop two filtering strategies to prune the search space while still guaranteeing an optimal solution. They compute an upper bound to the number of target compounds eliminated and a lower bound to the side-effect respectively. Our experiments on the human metabolic network demonstrate that the proposed algorithm can accurately identify the target enzymes for known successful drugs in the literature. Our experiments also show that OPMET can reduce the total search time by several orders of magnitude as compared to the exhaustive search.
Introduction
In pharmaceutics, the development of every drug mainly involves target identification, validation and lead inhibitor identification 9 . Traditional drug discovery approaches focus more on the efficacy of drugs than their toxicity (untoward side effects). Lack of predictive models that account for the complexity of the inter-relationships between the metabolic processes often leads to drug development failures. Toxicity and/or lack of efficacy can result if metabolic network components other than the intended target are affected. The current focus is on identification of biological targets (gene products, such as enzyme or protein) for drugs, which can be manipulated to produce the desired effect (of curing a disease) with minimum disruptive side-effects 23, 27 . Enzymes catalyze reactions, which produce metabolites (compounds) in the metabolic networks of organisms. Enzyme malfunctions can result in the accumulation of certain compounds which may result in diseases. We term such compounds
Problem definition
We develop a graph based representation that captures the interactions between reactions, compounds, and enzymes. Our graph representation is a variation of the boolean network model 24, 16 . R, C, and E denote the set of reactions, compounds, and enzymes respectively. The vertex set consists of all the members of R ∪ C ∪ E. A vertex is labeled as reaction, compound, or enzyme based on the entity it refers to. Let V R , V C , and V E denote the set of vertices from R, C, and E. A directed edge from vertex x to vertex y is then drawn if one of the following three conditions holds: (1) x represents an enzyme that catalyzes the reaction represented by y. (2) x corresponds to a substrate for the reaction represented by y. (3) x represents a reaction that produces the compound mapped to y. Figure 1 . A graph constructed for a hypothetical metabolic network with three reactions R 1 , R 2 , and R 3 , two enzymes E 1 and E 2 , and nine compounds C 1 , · · · , C 9 . Circles, rectangles, and triangles denote compounds, reactions, and enzymes respectively. Here, C 4 (shown by double circle) is the target compound. Dotted lines indicate the subgraph removed due to inhibition of enzyme E 2 . Figure 1 illustrates a small hypothetical metabolic network. In this figure, C 4 is the target compound (i.e., the production of C 4 should be stopped). In order to stop the production of C 4 , R 2 has to be prevented from taking place. The obvious solution is to disrupt one of its catalyzing enzymes (E 2 in this case). Another is by stopping the production of one of its reactant compounds (C 2 or C 3 in this case). If we stop the production of C 2 , we need to recursively look for the enzyme which is indirectly responsible for its production (E 1 in this case). Thus, the production of the target compound can be stopped by manipulating either E 1 or E 2 . Figure 1 shows the disruption of E 2 and its effect on the network. Inhibiting E 2 results in the knock out of compounds C 5 , C 8 and C 9 in addition to the target compound, C 4 . Note that the production of C 7 is not stopped since it is produced by R 1 even after the inhibition of E 2 . We define the number of non-target compounds knocked out as the damage, the manipulation of an enzyme set causes to the metabolic network. In this case, the damage of inhibiting E 2 is 3 (i.e., C 5 , C 8 and C 9 ). The damage of inhibition of E 1 is 2 (i.e., C 2 and C 5 ). The important observation is that E 1 and E 2 both achieve the effect of disrupting the target compound, C 4 . Hence, E 1 and E 2 are both potential drug targets. However, E 1 is a better drug-target than E 2 since it causes lesser damage.
Formally the optimal enzyme combination identification problem is: "Given a set of target compounds T (T ⊂ C), find the set of enzymes X (X ⊆ E) with minimum damage, whose inhibition stops the production of all the compounds in T ."
For simplicity, we assume that the input compounds to all reactions are present in the network and that there are no external inputs. Different enzymes and compounds may have varying levels of importance in the metabolic network. We consider all the enzymes and compounds to be of equal importance. This assumption can be relaxed by assigning weights to enzymes and compounds based on their role in the network. Also, we are not incorporating back-up enzyme activities 20 in this paper. This can be achieved by creating vertices for sets of enzymes in our graph representation. However, we do not discuss these extensions in this paper.
Proposed methods
This section proposes OPMET, a branch and bound algorithm that considerably reduces the number of possible combinations to be searched while still guaranteeing to find an optimal solution. Section 3.1 describes the basic branch and bound algorithm. Our prioritization (Section 3.2) and filtering (Section 3.3) strategies further improve this algorithm by reducing the search space.
3.1. State space and basic search strategy of OPMET Let E = {E i | ∀i, 1 ≤ i ≤ m} denote the set of enzymes for a metabolic network. The search space is modeled as a tree structure. Every node of this tree corresponds to a state in the search space and it is represented by a 4-tuple ([e π1 , e π2 , · · · , e πm ], k, d, remove). Here, π 1 , · · · , π m is a permutation of 1, 2, · · · , m. The first parameter corresponds to the state of all the enzymes (i.e., e πi corresponds to enzyme E i ). e πi = 1 if E i is inhibited. Otherwise, e πi = 0. The parameter k indicates that the first k enzymes are considered at that search state. The decision to inhibit or not inhibit has been fixed for enzymes from 1 to k − 1 and we now set e π k = 1 and e πi = 0, ∀i, k < i ≤ m. The damage incurred due to inhibited enzymes at that state is represented by d. The final parameter, remove, is a boolean variable. It takes value True if the inhibited enzymes stop the production of all the target compounds. Otherwise, it is set to False. We call a node with remove = True as a true node, and a node with remove = False as a false node. OPMET Algorithm: We start with the root node ([0, 0, · · · , 0], 0, 0, False) indicating that all enzymes are present in the network. As the search space is traversed, we keep the true node with the minimum damage found so far as the current true solution and store the associated damage value as D, the global cut-off threshold. D is initialized to the number of compounds in the network. At any point, we have an active set of nodes A, stored in a stack structure. A contains the nodes currently being considered. Let node N = ([e π1 , e π2 , · · · , e πm ], k, d, remove) be the node on top of this stack (i.e., the node to be evaluated). There are three cases:
• Case 1: N has damage d > D. In this case we prune the subtree rooted at N . We then backtrack.
• Case 2: N is a true node with damage d < D. In this case, we save N as the current true solution and update D with the damage value of N . We then backtrack.
• Case 3: N is a false node with damage d < D. In this case, we insert N in the active set A for backtracking purposes. We then create a new node N by setting e π k+1 = 1 in N (i.e., we inhibit the enzyme E π k+1 ). The resulting node is N = ([e π1 , e π2 , · · · , e πm ], k + 1, d , remove ). The node N is evaluated in the next step similarly.
Backtracking involves following steps. First we pick the top node from the active nodes stack A. Let N = ([e π1 , e π2 , · · · , e πm ], k , d , remove ) denote this node. We then set e π k +1 = 0 (indicating the node we are backtracking from) and e π k +2 = 1 in N (i.e., we inhibit the enzyme e π k +2 ). The resulting node becomes the node to be evaluated in the next step. The first two cases above stop expanding the tree at the current node. The former one implies that the current node is a possible solution. The latter one implies that the current node incurs too much damage to lead to a possible solution. The third case happens when the current node does not stop production of all the target compounds, but the damage is lower than the damage of the current best solu-tion. Such nodes may produce a possible solution with the inhibition of more enzymes. Thus, they need to be explored further to ensure that we find an optimal solution. The search terminates when there are no more nodes to explore. At this stage, the current true solution is the optimal solution.
Improving the OPMET algorithm by enzyme prioritization
In order to benefit from the pruning power of OPMET cases 1 and 2 (see Section 3.1), we need to compute the permutation π 1 , · · · , π m carefully. The earlier we place the enzymes in the optimal solution in this permutation, the better, as OPMET reaches the optimal solution earlier under such an ordering. Thus, reaching the solution with the smallest possible damage value (i.e., the optimal solution) increases the chances of pruning the remaining nodes of the search tree. This section develops a cost model to prioritize the enzymes dynamically.
Cost model
We develop a cost model as the basis for enzyme ordering in OPMET. This cost model takes both the observed and potential damage resulting from the inhibition of an enzyme set into the cost computation. For each enzyme E i ∈ E, we compute a weight W (E i ) as W (E i ) = 0 if E i inhibited and W (E i ) = 1 otherwise. We assign fractional weights between 0 and 1 to the reaction and compound nodes and the edges. Intuitively, the weight of a node or edge denotes the rate at which that node or edge appears in the network. The weight of each node is calculated as follows:
• Cost Rule 1: Let R j be a reaction node. Let w i , 1 ≤ i ≤ k, denote the weights of the incoming edges to R j . We compute the weight of
This is intuitive since a reaction takes place only if all the inputs are present.
• Cost Rule 2: Let C j be a compound node. Let w i , 1 ≤ i ≤ k, denote the weights of the incoming edges to C j . We compute the weight of
This weight evaluates to zero only if all the reactions that produce C j stops.
We define the weight of an edge as the weight of the node for which it is the outgoing edge. In order to compute the cost of E i , we set the weight of E i to zero (i.e., W (E i ) = 0). The weights of all the reaction and compound nodes are assigned progressively by a breadth-first search, according to the above scheme. The weights of all the nodes and edges which can be reached from E i are recomputed to reflect the change. We define an impact vector for each enzyme based on the effects of its inhibition. Definition 3.1. Given a network with n compounds,
denote the weight of the node corresponding to C j after the inhibition of enzyme E i . We define the impact vector of E i as I(
The impact vector of an enzyme approximates the amount of each compound that remains after the inhibition of that enzyme. Every entry of the impact vector is a fractional number between 0 and 1, where 0 indicates that the corresponding compound does not exist after inhibition of the corresponding enzyme. We define the cost of an enzyme as follows: Definition 3.2. Given a network with n compounds, C j , 1 ≤ j ≤ n. Assume that the compounds C j , ∀j, 1 ≤ j ≤ k ≤ n constitute the set of target compounds. Assume that the remaining compounds C j , ∀j, k + 1 ≤ j ≤ n constitute the non-target compounds.
Each target compound contributes a positive value and each non-target compound contributes a negative value to the cost of an enzyme. This is justified since the cost promotes removal of target compounds and demotes the removal of non-target compounds.
Ordering of enzymes in OPMET
Based on the impact vector of individual enzymes, we propose an incremental strategy for ordering of enzymes in OPMET. Let R = [r 1 , r 2 , · · · , r n ] denote the remaining fractions of compounds. Here, r i ∈ [0, 1] corresponds to compound C i , ∀i. We initialize r i = 1, ∀i indicating that all compounds are being produced without any disruption. Let V be the normalization vector as given in Definition 3.2. Let I(E i ) be the impact vector of enzyme E i (see Definition 3.1). Assume N = ([e π1 , e π2 , · · · , e πm ], k, d, remove) be the node currently being evaluated (i.e., the decision to inhibit or not inhibit has been fixed for e π1 , e π2 , · · · , e π k−1 ). We now need to decide which enzyme has to be evaluated next. In details, for every enzyme in the remaining enzyme set (e πi , ∀i, k ≤ i ≤ m), we compute the new remaining fractions of compounds (R i ). This is done by a Vector Direct Product of R and the impact vector of E i (I(E i )). That is,
The resulting vector R i is an approximation to the impact of inhibition of the enzyme E i in addition to already inhibited enzymes. This is justified since the quantity of a compound eliminated by a combination including E i will be at least as much as the quantity eliminated by E i alone. A good candidate enzyme at this step is the one that ensures that lesser of the target compounds remain after its inhibition. Also, it should ensure that the non target compounds suffer the minimum possible damage. Our cost model satisfies these requirements. Then, we compute the cost of each enzyme as the dot product of R i and V . That is,
Suppose that the enzyme (E j ) is with the minimum cost, that is, j = arg min j {Cost(E j )}. Based on the minimum cost, we update the ratio R = R j and select E j as the next enzyme to inhibit. Thus, this strategy chooses the next best enzyme to inhibit dynamically.
The cost of finding the best enzyme takes O(mn), where m and n denote the number of enzymes and compounds in the metabolic network respectively. This is because a vector product costs O(n), and O(m) such products are carried out.
Filtering strategies
So far, we have described how OPMET traverses the state space. In this section we propose two filtering strategies to eliminate large portions of the search space quickly while still guaranteeing the optimal solution. The following theorem (proof is not given to save the space) establishes a relationship between the impact of enzymes and their damage.
Theorem 3.1. Let E = {E 1 , E 2 , · · · , E r } be a set of enzymes. Let C j be a compound in the metabolic network. Let d i (C j ), 1 ≤ i ≤ r, denote the impact of E i on C j . If the inhibition of all the enzymes in E stops the production of C j , then
Next, we describe our filtering strategies. Target Filter: A combination of enzymes can not be the solution if their inhibition does not delete all the target compounds. This is the motivation behind our Target filter. The target filter eliminates a bulk of the search space when it is proven that there is no combination of enzymes in this space that can stop the production of all the target compounds (i.e., there is no useful drug target). This filtering strategy is based on Theorem 3.1. Formally, let node N = ([e π1 , e π2 , · · · , e πm ], k, d, False) be a node in the search space. Let T denote the set of target compounds. Backtrack if
In this inequality, the first term indicates the impact of enzymes, which are currently part of the solution set, on the target compounds. The second term represents the impact of the remaining enzymes on the target compounds. Non-target Filter: This filter quickly determines if there is any solution in the subtree with a damage d < D, the global cut-off threshold (see Subsection 3.1). This filter utilizes Theorem 3.1 similar to the Target Filter. The idea is as follows. At a given node N , for each target compound, C, we find the minimum number of enzymes, m such that
This gives us the minimum number of enzymes needed to delete C. Let m max be the maximum value of m for any target compound (i.e, we will need at least m max enzymes to delete the entire target compound set). Now, we sort the remaining enzymes (enzymes not considered so far) in the ascending order of their damage values. Let d max be the damage of the enzyme at index m max . If d max in addition to the damage incurred so far is greater than D, we prune the sub tree rooted at N .
Experimental results
We verify the biological validity of the proposed algorithm by employing it on known existing drugs. We evaluate the performance of the OPMET algorithm using the following three criteria: 1) Number of nodes generated: It represents the total number of enzyme combinations tested to complete the search. 2) Optimal node rank: This indicates the number of nodes explored before the method arrives at the optimal solution.
3) Execution time:
This indicates the total time taken by the method to finish the search.
We extracted the metabolic network information of E. Coli from KEGG 15 . The metabolic network in KEGG is divided into smaller networks according to their specific functions. We chose six of these networks for our experiments, based on the number of enzymes. We devised a labeling scheme for the networks which begins with 'N' and is followed by the number of enzymes in the network. For instance, 'N20' indicates a network with 20 enzymes. For each network, we constructed query sets of sizes one, two and four target compounds, by randomly choosing compounds from that network. Each query set contains 10 queries. Qualitative analysis of OPMET: We first evaluate how well the proposed cost model reflects the biological process. We do this by querying well studies drugs in the literature using OPMET. KEGG contains a database of known drug molecules along with the enzymes they inhibit and their therapeutic category. We use the drugs at this database as our benchmarks. Due to space limitation, we report only four of them. The value in parenthesis that starts with letter "D", "C", or "E" (e.g., D02562) is the unique identifier assigned to the corresponding drug, compound, or enzyme respectively in KEGG.
Benoxaprofen (D03080).
This drug inhibits arachidonate 5-lipoxygenase (E1.13.11.34) which appears in several networks including arachidonic acid metabolism network (hsa00590). In Pharmacology, 5-lipoxygenase inhibitors will decrease the biosynthesis of LTB4 (C02165), cysteinylcontaining leukotrienes LTC4 (C02166), LTD4 (C05951) and LTE4 (C05952). According to our graph model, the removal of 5-lipoxygenase eliminates three of these compounds LTB4, LTC4 and LTD4 in arachidonic acid metabolism network. Inhibition of this enzyme also eliminates five more compounds, namely 5(S)-HPETE (C05356), 5-HETE (C04805), LTA4 (C00909), 20-OH-LTB4 (C04853) and 9(S)-HPOD (C14827). These compounds can be considered as damage in our model. Running OPMET with LTB4, LTC4, LTD4 and LTE4 as the target compound finds LTA4H (E3.3.2.6) and LTC4 synthase (E4.4.1.20) as the optimal enzyme set. The inhibition of these enzymes eliminates only one non-target compound, 20-OH-LTB4 (C04853). OPMET potentially finds a better solution in this experiment than the existing drug as the same compound is eliminated by the existing drug in addition to four other compounds. Indeed, recent research supports our model since the anti-inflammatory effect of the levels of LTA4H 22 and LTC4 29 have been observed. 2. Rasagiline (D02562). This is an antiparkinsonian drug. It inhibits amine oxidase (E.1.4.3.4) which appears in several metabolic networks. In the histidine metabolism network (hsa00340), the removal of amine oxidase eliminates the compounds Methylimidazole acetaldehyde (C05827) Methylimidazoleacetic acid (C05828) according to our graph model. Levels of pros-methylimidazoleacetic acid has correlation with severity of Parkinson's disease in patients 3, 21 . This demonstrates that, our model can predict the intended target well. When OPMET is run on the same network with methylimidazoleacetic acid and the methylimidazole acetaldehyde as the target compounds it finds amine oxidase as the optimal target. This implies that Rasgiline is targeting the optimal enzyme according to our model. For Ozagrel (D01683) and Erythromycin acistrate (D02523), running OPMET can find the same target enzyme as the actual drug. (details omitted) Evaluation of prioritization strategies: We compare our OPMET algorithm with a random ordering of enzymes and an exhaustive search. We do not include our filtering strategies here as the goal is to focus on the enzyme ordering. We present the results only up to a network of size 20 enzymes. This is because, beyond this, the search space grows rapidly, necessitating the use of filtering strategies. Table 1 shows the average number of nodes generated and the average optimal node rank of OPMET to that of an exhaustive search. The results show that OPMET with dynamic enzyme ordering is the best strategy for all the tested networks. It generates the least number of nodes in all the experiments. All the methods generate significantly large number of nodes for N17. This is because the number of reactions and compounds of this network is much larger than the other networks, resulting in more interactions in the network. OPMET has small Optimal Node Ranks. On an average, it arrives at the optimal solution within the generation of 0.008 % of the number of nodes possible in an exhaustive search. This is significantly better than the random ordering which arrives at the optimal solution within the generation of 11 %. Evaluation of filtering strategies: We measure how much our filtering strategies reduce the search space. The experiments are performed using OPMET with dynamic enzyme ordering. Table 2 shows the average number of nodes generated, the average optimal node rank and the average execution time for the combined filters. The combined filters show the best pruning. On an average, the combined filters prune 91.5 % of the nodes generated in the method without filters. We also see that most of this benefit is obtained from the Target Filter (it filters 91.4 % of the nodes generated by the method without filters). The combined filter generates only 12700 nodes for N28 (0.004 % of an exhaustive search). All the methods have the same optimal node rank for networks except N24. This suggests that OPMET yielded the optimal solution as early as possible for these networks. For N24, the combined filter shows that filtering strategies can also lead to advancement in finding the optimal solution. For N24, Target filter arrives at the optimal solution 99 % earlier and the combined filters arrive at the optimal solution 99.9 % earlier than the method without filters (the additional 0.9 % improvement is obtained from the non-target filter). We observe that the target filter is more efficient than the non-target filter and the combined filter has the best performance. We observe that there is no clear correlation between the size of the target compound set and the number of nodes explored (results are not shown due to space limitation).
Related Work
Classical drug discovery approaches involve incorporating a large number of hypothetical targets into in-vitro or cell-based assays and performing automated high throughput screening (HTS) of vast chemical compound libraries 30, 9 . Post-genomic advances in bioinformatics have fostered the development of rational drug-design methods and reduction of serious side-effects 8, 5, 4 . This has engendered the concept of reverse pharmacology 27 , in which, the first step is the identification of protein targets, that may be critical intervention points in a disease process 23, 1 . The reverse approach is driven by the mechanics of the disease and hence is expected to be more efficient than the classical approach 27 . Rapid identification of enzyme (or protein) targets needs a thorough understanding of the underlying metabolic network of the organism affected by a disease. The availability of fully sequenced genomes has enabled researchers to integrate the available genomic information to reconstruct and study metabolic networks 28, 13 . These studies have revealed important properties of these networks 10, 2, 18 . The potential of an enzyme to be an effective drug target is considered to be related to its essentiality in the corresponding metabolic network 14 . Lemke et. al proposed the measure enzyme damage as an indicator of enzyme essentiality 17, 19 . Recently, a computational approach for prioritizing potential drug targets for antimalarial drugs has been developed 31 . A choke-point analysis of P.falciparcum was performed to identify essential enzymes which are potential drug targets. The possibility of using enzyme inhibitors as antiparasitic drugs is being investigated through stoichiometric analysis of the metabolic networks of parasites 6, 7 . These studies show the effectiveness of computational techniques in reverse pharmacological approaches.
A combination of microarray time-course data and gene-knockout data was used to study the effects of a chemical compound on a gene network
12 . An investigation of metabolite essentiality is carried out with the help of stoichiometric analysis 11 . These approaches underline the importance of studying the role of compounds (metabolites) during the pursuit of computational solutions to pharmacological problems.
Conclusions
In this paper, we formulated the optimal enzyme-combination identification problem as an optimization problem on metabolic networks. We proposed OPMET, a branch-and-bound algorithm to explore the search space dynamically. We also developed two filtering strategies to prune the search space while still guaranteeing an optimal solution. The filters compute an upper bound to the number of target compounds deleted and a lower bound to the side-effect respectively.
Our experiments on the human metabolic network demonstrates that the proposed model can accurately identify the target enzymes for known successful drugs in the literature. More specifically, OPMET found the same target enzyme as Rasagiline, Ozagrel, and Erythromycin acistrate when their target compounds are given as input. OPMET found a different set of enzymes than Benoxaprofen for the target compounds of Benoxaprofen. OPMET's solution in this case has a great potential to be better than Benoxaprofen since OPMET's solution damages only one non-target compound whereas Benoxaprofen damages five non-target compounds including the compound damaged by OPMET's solution. Our experiments also show that OPMET can reduce the total search time by several orders of magnitude as compared to the exhaustive search. The optimal solution is reached by OPMET within the exploration of 0.005 % of the total search space on an average, proving that our methods are effective in approximating the impact of an enzyme on a compound. OPMET with combined filters pruned 91.6 % of the search space on average.
